Table 1.

Mutated tyrosine kinases in human malignancies


Tyrosine kinase

Malignancy
BCR-ABL   CML 
  ALL 
  AML 
TEL-ABL   ALL 
  AML 
  Atypical CML 
PDGFR-β   CMML7-11  
  AML12  
TEL-Jak2   Atypical CML13  
  ALL14  
ALK-1   Anaplastic large cell lymphoma15  
RET   MEN216,17  
  Papillary thyroid carcinoma18  
EGFR   Glioblastoma multiforme19  
  Nonsmall cell lung cancer20  
TPR-TRK   Papillary thyroid cancer21  
TPR-MET   Gastric carcinoma22  
FLT3   AML23  
  MDS24  
  ALL23  
PDGFR-α   HES25  
  Systemic mast cell disease26  
  GIST27  
c-KIT   AML28,29  
  Mastocytosis/mast cell  
  leukemia30,31  
  GIST32,33  
c-met   Lung cancer34  
c-fms   AML, MDS35-37  
  CMML38  
FGFR
 
MPD/AML39 
 

Tyrosine kinase

Malignancy
BCR-ABL   CML 
  ALL 
  AML 
TEL-ABL   ALL 
  AML 
  Atypical CML 
PDGFR-β   CMML7-11  
  AML12  
TEL-Jak2   Atypical CML13  
  ALL14  
ALK-1   Anaplastic large cell lymphoma15  
RET   MEN216,17  
  Papillary thyroid carcinoma18  
EGFR   Glioblastoma multiforme19  
  Nonsmall cell lung cancer20  
TPR-TRK   Papillary thyroid cancer21  
TPR-MET   Gastric carcinoma22  
FLT3   AML23  
  MDS24  
  ALL23  
PDGFR-α   HES25  
  Systemic mast cell disease26  
  GIST27  
c-KIT   AML28,29  
  Mastocytosis/mast cell  
  leukemia30,31  
  GIST32,33  
c-met   Lung cancer34  
c-fms   AML, MDS35-37  
  CMML38  
FGFR
 
MPD/AML39 
 

MEN2 indicates multiple endocrine neoplasia 2 syndrome.

Close Modal

or Create an Account

Close Modal
Close Modal